A 39-Country Survey of the Blood Typing, Grouping and Infectious Disease Screening Market--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

VPGMarketResearch
1025 Pages - VPBB16056
$33,500.00

This comprehensive 39-country report from VPGMarketResearch.com contains 1,025 pages, 387 tables and provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new product development and marketing strategies.

The report explores future market and technological trends; provides test volume and sales forecasts by market segment/test location; compares features of major automated and semi-automated molecular and immunohematology analyzers; profiles leading and emerging competitors; and identifies specific product and market opportunities facing suppliers during the next five years.

Blood Group Genotyping

PCR, PCR-RFLP, AS-PCR or PCR-SSP, Multiplex PCR, Real Time PCR, Sanger DNA Sequencing, Pyrosequencing

Microarrays

BeadChip Array, BloodChip, Genome Lab SNP Stream, Fluidic Microarray Systems, TaqMan OpenArray, MALDI-TOF-MS, Mini-Sequencing

Blood Typing and Grouping Tests

ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 + IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du).

Infectious Disease Screening Tests

AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NAT.

Sales and Market Share Analysis

Sales and market share estimates for leading suppliers of blood typing, grouping and infectious disease screening tests in major countries.

Countries Analyzed in the Report

Armenia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Latvia, Luxembourg, Malta, Moldova, Montenegro, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, UK, USA

Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, M&A, product portfolios, marketing tactics, and new products in R&D.

Market Segmentation Analysis

- Comprehensive market segmentation analysis, including review of the market dynamics, trends, structure, size, growth, and key suppliers.

- Test volume and sales forecasts for over 40 blood typing, grouping and infectious disease screening tests, including NAT assays.

Current and Emerging Products

- Analysis of current and emerging molecular blood typing, grouping and infectious disease NAT screening assays.

- Review of automated and semi-automated molecular and immunohematology analyzers.

Technology Review

- Assessment of current and emerging technologies, and their potential applications for the blood banking market.

- Companies developing or marketing new technologies and products, by test.

Strategic Recommendations

- New product development opportunities for molecular blood typing, grouping and infectious disease NAT assays and instrumentation with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Contains 1,025 pages and 387 tables

$33,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838